{"id":"fgfr2","name":"FGFR2","symbol":"FGFR2","route":"/targets/fgfr2/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3689","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000066468","uniprot":"https://www.uniprot.org/uniprotkb/P21802/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P21802","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4142","open-targets":"https://platform.opentargets.org/target/ENSG00000066468","civic":"https://civicdb.org/genes/2263/summary","oncokb":"https://www.oncokb.org/gene/FGFR2","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FGFR2","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=FGFR2","depmap":"https://depmap.org/portal/gene/FGFR2?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000066468-FGFR2","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/2263","omim":"https://www.omim.org/entry/176943"}],"products":[{"id":"absk061","name":"ABSK061","status":"phase-2","modality":"small molecule (structure undisclosed or not yet in PubChem)","route":"/drugs/absk061/"},{"id":"anlotinib","name":"Anlotinib","status":"approved","modality":"Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, KIT)","route":"/drugs/anlotinib/"},{"id":"bemarituzumab","name":"Bemarituzumab","status":"phase-3","modality":"Monoclonal antibody (anti-FGFR2b)","route":"/drugs/bemarituzumab/"},{"id":"cgt4859","name":"CGT4859","status":"phase-2","modality":"small molecule (structure undisclosed or not yet in PubChem)","route":"/drugs/cgt4859/"},{"id":"erdafitinib","name":"Erdafitinib","status":"approved","modality":"Small-molecule kinase inhibitor (pan-FGFR)","route":"/drugs/erdafitinib/"},{"id":"futibatinib","name":"Futibatinib","status":"approved","modality":"Small-molecule irreversible kinase inhibitor (FGFR1-4)","route":"/drugs/futibatinib/"},{"id":"hmpl-453","name":"HMPL-453","status":"phase-3","modality":"small molecule (structure undisclosed or not yet in PubChem)","route":"/drugs/hmpl-453/"},{"id":"infigratinib","name":"Infigratinib","status":"withdrawn","modality":"Oral FGFR1 to 3 kinase inhibitor","route":"/drugs/infigratinib/"},{"id":"lenvatinib","name":"Lenvatinib","status":"approved","modality":"Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, RET, KIT)","route":"/drugs/lenvatinib/"},{"id":"lirafugratinib","name":"Lirafugratinib","status":"approved","modality":"Small-molecule FGFR2 inhibitor","route":"/drugs/lirafugratinib/"},{"id":"nintedanib","name":"Nintedanib","status":"approved","modality":"Small-molecule kinase inhibitor (VEGFR/FGFR/PDGFR)","route":"/drugs/nintedanib/"},{"id":"pemigatinib","name":"Pemigatinib","status":"approved","modality":"Small-molecule kinase inhibitor (FGFR1-3)","route":"/drugs/pemigatinib/"},{"id":"tar-210","name":"TAR-210","status":"phase-3","modality":"small molecule (intravesical drug-releasing system)","route":"/drugs/tar-210/"},{"id":"therascreen-cdx","name":"therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)","status":"approved","modality":"Real-time PCR companion diagnostic test family","route":"/drugs/therascreen-cdx/"},{"id":"tinengotinib","name":"Tinengotinib","status":"phase-3","modality":"Small-molecule multi-kinase inhibitor (FGFR1-3, VEGFR, Aurora, JAK)","route":"/drugs/tinengotinib/"},{"id":"tyra-300","name":"TYRA-300","status":"phase-2","modality":"small molecule","route":"/drugs/tyra-300/"}],"trials":[{"id":"nct04194775","name":"A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma","nct":"NCT04194775","phase":"3","status":"active"},{"id":"emerald-3","name":"EMERALD-3","nct":"NCT05301842","phase":"3","status":"positive"},{"id":"fight-302","name":"FIGHT-302","nct":"NCT03656536","phase":"3","status":"withdrawn"},{"id":"nct04586231","name":"LITESPARK-011","nct":"NCT04586231","phase":"3","status":"positive"},{"id":"litespark-012","name":"LITESPARK-012","nct":"NCT04736706","phase":"3","status":"negative"},{"id":"fortitude-101","name":"FORTITUDE-101","nct":"NCT05052801","phase":"3","status":"mixed"},{"id":"leap-012","name":"LEAP-012","nct":"NCT04246177","phase":"3","status":"mixed"},{"id":"thor","name":"THOR","nct":"NCT03390504","phase":"3","status":"positive"},{"id":"leap-002","name":"LEAP-002","nct":"NCT03713593","phase":"3","status":"negative"},{"id":"clear","name":"CLEAR (KEYNOTE-581)","nct":"NCT02811861","phase":"3","status":"positive"},{"id":"keynote-775","name":"KEYNOTE-775 / Study 309","nct":"NCT03517449","phase":"3","status":"positive"},{"id":"reflect","name":"REFLECT","nct":"NCT01761266","phase":"3","status":"positive"},{"id":"lume-lung-1","name":"LUME-Lung 1","nct":"NCT00805194","phase":"3","status":"mixed"},{"id":"nct06469879","name":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients","nct":"NCT06469879","phase":"3","status":"planned"},{"id":"nct06048315","name":"A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs W","nct":"NCT06048315","phase":"3","status":"planned"},{"id":"nct07728955","name":"A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for","nct":"NCT07728955","phase":"3","status":"planned"},{"id":"nct06371157","name":"A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat","nct":"NCT06371157","phase":"3","status":"recruiting"},{"id":"nct04854668","name":"A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Can","nct":"NCT04854668","phase":"3","status":"active"},{"id":"nct05899049","name":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study","nct":"NCT05899049","phase":"3","status":"active"},{"id":"nct06919965","name":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","nct":"NCT06919965","phase":"3","status":"recruiting"},{"id":"nct06319820","name":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer","nct":"NCT06319820","phase":"3","status":"recruiting"},{"id":"nct05862337","name":"Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.","nct":"NCT05862337","phase":"3","status":"recruiting"},{"id":"nct07443397","name":"Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.","nct":"NCT07443397","phase":"3","status":"recruiting"},{"id":"nct07405164","name":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","nct":"NCT07405164","phase":"3","status":"recruiting"},{"id":"first-308","name":"FIRST-308","phase":"3","status":"recruiting"},{"id":"nct07710885","name":"Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer","nct":"NCT07710885","phase":"3","status":"recruiting"},{"id":"nct07745296","name":"Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer","nct":"NCT07745296","phase":"3","status":"planned"},{"id":"nct03016819","name":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)","nct":"NCT03016819","phase":"3","status":"recruiting"},{"id":"safir-abc10","name":"SAFIR-ABC10","nct":"NCT05615818","phase":"3","status":"recruiting"},{"id":"nct05948475","name":"Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma","nct":"NCT05948475","phase":"3","status":"active"},{"id":"nct06441344","name":"Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell","nct":"NCT06441344","phase":"3","status":"planned"},{"id":"lume-meso","name":"LUME-Meso","nct":"NCT01907100","phase":"2/3","status":"negative"},{"id":"alter-0303","name":"ALTER 0303","nct":"NCT02388919","phase":"2/3","status":"positive"},{"id":"nct04322617","name":"Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer","nct":"NCT04322617","phase":"2/3","status":"recruiting"},{"id":"nct06662877","name":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","nct":"NCT06662877","phase":"2/3","status":"planned"},{"id":"nct06506955","name":"Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.","nct":"NCT06506955","phase":"2/3","status":"active"},{"id":"nct04353375","name":"HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma","nct":"NCT04353375","phase":"2/3","status":"recruiting"},{"id":"nct07636226","name":"QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer","nct":"NCT07636226","phase":"2/3","status":"planned"},{"id":"pediatric-match","name":"NCI-COG Pediatric MATCH (APEC1621)","nct":"NCT03155620","phase":"platform","status":"active"},{"id":"nct02159066","name":"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma","nct":"NCT02159066","phase":"2","status":"completed"},{"id":"nct02365597","name":"An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer","nct":"NCT02365597","phase":"2","status":"active"},{"id":"fight-202","name":"FIGHT-202","nct":"NCT02924376","phase":"2","status":"positive"},{"id":"nct01975701","name":"A Phase 2 Study of BGJ398 in Patients With Recurrent GBM","nct":"NCT01975701","phase":"2","status":"completed"},{"id":"nct05913089","name":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer","nct":"NCT05913089","phase":"2","status":"recruiting"},{"id":"nct06632262","name":"A Phase 2 Clinical Study of ABSK061 and ABSK043","nct":"NCT06632262","phase":"2","status":"recruiting"},{"id":"nct07562581","name":"A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC","nct":"NCT07562581","phase":"2","status":"recruiting"},{"id":"nct07052253","name":"A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.","nct":"NCT07052253","phase":"2","status":"recruiting"},{"id":"nct06906562","name":"A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic","nct":"NCT06906562","phase":"2","status":"recruiting"},{"id":"nct07679399","name":"A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.","nct":"NCT07679399","phase":"2","status":"recruiting"},{"id":"nct06728410","name":"A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement","nct":"NCT06728410","phase":"2","status":"recruiting"},{"id":"nct07815223","name":"A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC","nct":"NCT07815223","phase":"2","status":"recruiting"},{"id":"nct07099794","name":"A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen","nct":"NCT07099794","phase":"2","status":"planned"},{"id":"nct07538271","name":"A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer","nct":"NCT07538271","phase":"2","status":"planned"},{"id":"nct06962787","name":"A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer","nct":"NCT06962787","phase":"2","status":"recruiting"},{"id":"nct05678270","name":"A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma","nct":"NCT05678270","phase":"2","status":"recruiting"},{"id":"nct07359820","name":"A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement","nct":"NCT07359820","phase":"2","status":"recruiting"},{"id":"nct07780838","name":"Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma","nct":"NCT07780838","phase":"2","status":"recruiting"},{"id":"nct07282262","name":"An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.","nct":"NCT07282262","phase":"2","status":"recruiting"},{"id":"nct07398326","name":"Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer","nct":"NCT07398326","phase":"2","status":"recruiting"},{"id":"nct07635290","name":"Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer","nct":"NCT07635290","phase":"2","status":"active"},{"id":"nct02706691","name":"BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer","nct":"NCT02706691","phase":"2"},{"id":"nct06901622","name":"Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma","nct":"NCT06901622","phase":"2","status":"recruiting"},{"id":"nct06992336","name":"Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy","nct":"NCT06992336","phase":"2","status":"recruiting"},{"id":"nct06767813","name":"Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms","nct":"NCT06767813","phase":"2","status":"recruiting"},{"id":"nct07548177","name":"Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma","nct":"NCT07548177","phase":"2","status":"recruiting"},{"id":"nct07829874","name":"Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.","nct":"NCT07829874","phase":"2","status":"planned"},{"id":"nct07159217","name":"Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer","nct":"NCT07159217","phase":"2","status":"planned"},{"id":"nct07081633","name":"Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma","nct":"NCT07081633","phase":"2","status":"active"},{"id":"nct06028633","name":"Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients","nct":"NCT06028633","phase":"2","status":"planned"},{"id":"nct07498478","name":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","nct":"NCT07498478","phase":"2","status":"recruiting"},{"id":"nct06995677","name":"Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer","nct":"NCT06995677","phase":"2","status":"recruiting"},{"id":"nct06963060","name":"Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)","nct":"NCT06963060","phase":"2","status":"recruiting"},{"id":"nct06389500","name":"HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer","nct":"NCT06389500","phase":"2","status":"planned"},{"id":"nct06849492","name":"HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer","nct":"NCT06849492","phase":"2","status":"planned"},{"id":"nct07263360","name":"Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","nct":"NCT07263360","phase":"2","status":"planned"},{"id":"nct05170438","name":"Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment","nct":"NCT05170438","phase":"2","status":"active"},{"id":"nct06919848","name":"Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)","nct":"NCT06919848","phase":"2","status":"planned"},{"id":"nct05903833","name":"Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge","nct":"NCT05903833","phase":"2","status":"recruiting"},{"id":"nct04976634","name":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","nct":"NCT04976634","phase":"2","status":"active"},{"id":"nct06230471","name":"Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer","nct":"NCT06230471","phase":"2","status":"recruiting"},{"id":"nct06530823","name":"Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma","nct":"NCT06530823","phase":"2","status":"planned"},{"id":"nct07786766","name":"Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma","nct":"NCT07786766","phase":"2","status":"recruiting"},{"id":"nct04846634","name":"Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (A","nct":"NCT04846634","phase":"2","status":"planned"},{"id":"nct05945823","name":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","nct":"NCT05945823","phase":"2","status":"active"},{"id":"nct06852287","name":"Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","nct":"NCT06852287","phase":"2","status":"recruiting"},{"id":"nct07530445","name":"Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer","nct":"NCT07530445","phase":"2","status":"recruiting"},{"id":"nct07670273","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer","nct":"NCT07670273","phase":"2","status":"recruiting"},{"id":"nct07704177","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer","nct":"NCT07704177","phase":"2","status":"recruiting"},{"id":"nct06892925","name":"QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors","nct":"NCT06892925","phase":"2","status":"active"},{"id":"nct07110064","name":"QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer","nct":"NCT07110064","phase":"2","status":"recruiting"},{"id":"nct07601178","name":"QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride","nct":"NCT07601178","phase":"2","status":"recruiting"},{"id":"nct07501169","name":"Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","nct":"NCT07501169","phase":"2","status":"planned"},{"id":"nct07025174","name":"Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer","nct":"NCT07025174","phase":"2","status":"recruiting"},{"id":"nct05112991","name":"Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer","nct":"NCT05112991","phase":"2","status":"recruiting"},{"id":"nct05775159","name":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer","nct":"NCT05775159","phase":"2","status":"active"},{"id":"nct05822752","name":"Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Bu","nct":"NCT05822752","phase":"2","status":"active"},{"id":"nct04875585","name":"Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC","nct":"NCT04875585","phase":"2","status":"recruiting"},{"id":"nct07219459","name":"Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)","nct":"NCT07219459","phase":"2","status":"recruiting"},{"id":"nct03473743","name":"A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer","nct":"NCT03473743","phase":"1/2","status":"active"},{"id":"foenix-cca2","name":"FOENIX-CCA2","nct":"NCT02052778","phase":"1/2","status":"positive"},{"id":"nct06682780","name":"A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours","nct":"NCT06682780","phase":"1/2","status":"recruiting"},{"id":"nct07269158","name":"A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer","nct":"NCT07269158","phase":"1/2","status":"planned"},{"id":"nct06378593","name":"A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations","nct":"NCT06378593","phase":"1/2","status":"recruiting"},{"id":"nct06777316","name":"A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors","nct":"NCT06777316","phase":"1/2","status":"active"},{"id":"nct04008797","name":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","nct":"NCT04008797","phase":"1/2","status":"active"},{"id":"nct05319730","name":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","nct":"NCT05319730","phase":"1/2","status":"recruiting"},{"id":"nct04300556","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","nct":"NCT04300556","phase":"1/2","status":"recruiting"},{"id":"nct07617805","name":"EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC","nct":"NCT07617805","phase":"1/2","status":"recruiting"},{"id":"nct04977453","name":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","nct":"NCT04977453","phase":"1/2","status":"recruiting"},{"id":"nct07636798","name":"Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer","nct":"NCT07636798","phase":"1/2","status":"recruiting"},{"id":"nct06761027","name":"mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer","nct":"NCT06761027","phase":"1/2","status":"recruiting"},{"id":"nct05024214","name":"Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors","nct":"NCT05024214","phase":"1/2","status":"recruiting"},{"id":"nct07139470","name":"Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer","nct":"NCT07139470","phase":"1/2","status":"planned"},{"id":"nct04938817","name":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","nct":"NCT04938817","phase":"1/2","status":"active"},{"id":"nct05544552","name":"Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations","nct":"NCT05544552","phase":"1/2","status":"active"},{"id":"nct05316155","name":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer","nct":"NCT05316155","phase":"1/2","status":"active"},{"id":"nct02861573","name":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","nct":"NCT02861573","phase":"1/2","status":"active"},{"id":"nct04626479","name":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","nct":"NCT04626479","phase":"1/2","status":"active"},{"id":"nct04626518","name":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","nct":"NCT04626518","phase":"1/2","status":"active"},{"id":"nct06140576","name":"The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breas","nct":"NCT06140576","phase":"1/2","status":"planned"},{"id":"nct06456138","name":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC","nct":"NCT06456138","phase":"1/2","status":"planned"}],"pathways":["fgfr-signalling","gastric-cancer-signalling","proteoglycans-in-cancer"],"companies":["abbisko","amgen","basilea","black-diamond-therapeutics","boehringer-ingelheim","bridgebio-oncology-therapeutics","cogent-biosciences","eisai","elevar-therapeutics","helsinn","hutchmed","incyte","johnson-johnson","merck","qiagen","relay-therapeutics","sino-biopharm","taiho","transthera","tyra-biosciences"],"keyPapers":["paper-philip-kras-wild-type-pancreatic-ccr-2022","paper-mody-biliary-ctdna-profiling-jco-po-2019","paper-javle-biliary-ngs-cancer-2016","paper-burstein-tnbc-genomic-subtypes-ccr-2015","paper-nakamura-biliary-genomic-spectra-nat-genet-2015"],"hotspots":[{"label":"Fusions (FGFR2::BICC1 and many partners)","position":768,"kind":"activating","frequency":"About 10 to 15% of intrahepatic cholangiocarcinoma","drugs":["pemigatinib","futibatinib","erdafitinib","tinengotinib"]},{"label":"N550K / N550H","position":550,"kind":"activating","drugs":["futibatinib","tinengotinib","erdafitinib"]},{"label":"V565I / V565F (gatekeeper) and E566A, L618V","position":565,"kind":"resistance","drugs":["futibatinib","tinengotinib"]}],"openQuestions":[{"id":"fgfr2-resistance","question":"Can FGFR2-selective inhibitors overcome the polyclonal kinase-domain mutations that end responses to pemigatinib and futibatinib?","stage":"translational","actor":"industry","source":{"label":"Goyal et al., Cancer Discov 2017","url":"https://doi.org/10.1158/2159-8290.CD-16-1000"}}],"assays":[{"id":"foundationone-cdx-panel","name":"FoundationOne CDx","cutoff":"Per companion claim: EGFR, ALK, BRAF V600, ERBB2 amplification, KRAS wild-type, BRCA1/2 and HRR genes, PIK3CA, MET exon 14, RET, FGFR2 fusions, IDH1, NTRK fusions; MSI-high; TMB at least 10 mutations per megabase"},{"id":"foundationone-liquid-cdx","name":"FoundationOne Liquid CDx","cutoff":"Per companion claim: EGFR (osimertinib, erlotinib, gefitinib), ALK (alectinib), BRCA1/2 and ATM (olaparib, rucaparib), PIK3CA (alpelisib), FGFR3 (erdafitinib), NTRK and RET; negative plasma results reflex to tissue"},{"id":"fgfr-therascreen","name":"therascreen FGFR RGQ RT-PCR Kit","cutoff":"Alteration detected (erdafitinib, urothelial carcinoma)"}],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}